JP2025513588A - 抗ｉｌｔ３抗体およびその使用 - Google Patents

抗ｉｌｔ３抗体およびその使用 Download PDF

Info

Publication number
JP2025513588A
JP2025513588A JP2024563035A JP2024563035A JP2025513588A JP 2025513588 A JP2025513588 A JP 2025513588A JP 2024563035 A JP2024563035 A JP 2024563035A JP 2024563035 A JP2024563035 A JP 2024563035A JP 2025513588 A JP2025513588 A JP 2025513588A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513588A5 (https=
Inventor
ペレッツ，ツリ
マンデル，イラナ
ピツェム，ヨアフ
イアンコビチ，リアット
ハキム，モッティ
シュルマン，アビドール
サピル，ヤイール
ベン－モシェ，テヒラ
Original Assignee
ビオンド バイオロジクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオンド バイオロジクス リミテッド filed Critical ビオンド バイオロジクス リミテッド
Publication of JP2025513588A publication Critical patent/JP2025513588A/ja
Publication of JP2025513588A5 publication Critical patent/JP2025513588A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024563035A 2022-04-25 2023-04-25 抗ｉｌｔ３抗体およびその使用 Pending JP2025513588A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263334365P 2022-04-25 2022-04-25
US63/334,365 2022-04-25
PCT/IL2023/050426 WO2023209716A1 (en) 2022-04-25 2023-04-25 Anti-ilt3 antibodies and use thereof

Publications (2)

Publication Number Publication Date
JP2025513588A true JP2025513588A (ja) 2025-04-24
JP2025513588A5 JP2025513588A5 (https=) 2026-05-07

Family

ID=86604937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563035A Pending JP2025513588A (ja) 2022-04-25 2023-04-25 抗ｉｌｔ３抗体およびその使用

Country Status (9)

Country Link
US (1) US20250277032A1 (https=)
EP (1) EP4514472A1 (https=)
JP (1) JP2025513588A (https=)
KR (1) KR20250025354A (https=)
CN (1) CN119487072A (https=)
AU (1) AU2023258644A1 (https=)
CA (1) CA3249138A1 (https=)
IL (1) IL316523A (https=)
WO (1) WO2023209716A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025062392A1 (en) * 2023-09-20 2025-03-27 Biond Biologics Ltd. Anti-ilt3 blockade combinations
WO2025141589A1 (en) 2023-12-31 2025-07-03 Biond Biologics Ltd. Treatment of cancer with anti-ilt3 antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
WO2013033734A1 (en) * 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
CA2977544C (en) * 2015-03-06 2023-12-19 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
EP3538141A4 (en) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. LIGAND ILT3
WO2018148494A1 (en) * 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
CN111712518B (zh) 2017-11-17 2025-03-25 默沙东有限责任公司 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
CA3109366A1 (en) 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
JP2022522775A (ja) * 2019-03-01 2022-04-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｌｉｌｒｂ４結合抗体およびその使用方法
PH12022551462A1 (en) 2019-12-19 2023-11-13 Ngm Biopharmaceuticals Inc Ilt3-binding agents and methods of use thereof
AU2021236302A1 (en) * 2020-03-12 2022-10-20 Immune-Onc Therapeutics, Inc. Novel anti-LILRB4 antibodies and derivative products

Also Published As

Publication number Publication date
US20250277032A1 (en) 2025-09-04
CN119487072A (zh) 2025-02-18
KR20250025354A (ko) 2025-02-21
WO2023209716A1 (en) 2023-11-02
EP4514472A1 (en) 2025-03-05
CA3249138A1 (en) 2023-11-02
AU2023258644A1 (en) 2024-12-05
IL316523A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
JP7320498B2 (ja) Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
KR102433076B1 (ko) Ilt2에 대한 항체 및 이의 용도
JP7685954B2 (ja) 低分子脱落遮断剤
BR112021004489A2 (pt) métodos de tratamento de toxicidade relacionada à imunoterapia usando um antagonista de gm-csf
US20250277032A1 (en) Anti-ilt3 antibodies and use thereof
EP4480966A1 (en) Humanized anti-cd28 antibody and bispecific antibody thereof with anti-cd40 antibody
JP2023509803A (ja) Ｍｍｐ抑制の使用
WO2023031943A2 (en) Cd28 shedding blocking agents
WO2025062392A1 (en) Anti-ilt3 blockade combinations
JP2024514255A (ja) 増強された抗ｈｖｅｍ抗体及びその使用
CN118541387A (zh) Cd28脱落阻断剂
WO2024176224A1 (en) Antibodies against hla-e and use thereof
WO2025215647A1 (en) Combination cancer treatment with staggered dosing
HK40064257A (en) Small shedding blocking agents
EP3997124A1 (en) Antibodies with reduced immunogenicity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260423